(CHE) Chemed - Overview
Stock: Hospice, Palliative, Plumbing, Drain, Restoration
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.46% |
| Yield on Cost 5y | 0.44% |
| Yield CAGR 5y | 11.96% |
| Payout Consistency | 96.1% |
| Payout Ratio | 14.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 25.3% |
| Relative Tail Risk | -13.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.70 |
| Alpha | -27.05 |
| Character TTM | |
|---|---|
| Beta | 0.246 |
| Beta Downside | 0.061 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.37% |
| CAGR/Max DD | -0.09 |
Description: CHE Chemed January 09, 2026
Chemed Corp (NYSE:CHE) operates two distinct businesses: VITAS, the nation’s largest hospice and palliative-care provider, and Roto-Rooter, a leading residential and commercial plumbing and water-damage-restoration franchise. The firm delivers clinical services-including nursing, social work, and spiritual counseling-to patients and families across the U.S., while Roto-Rooter generates revenue through company-owned branches, independent contractors, and franchisees offering plumbing, drain cleaning, excavation, and water-restoration services.
Key drivers to watch: (1) VITAS’s revenue has grown at a 7% CAGR over the past three years, supported by an aging U.S. population and increasing Medicare enrollment for hospice care; (2) Roto-Rooter contributes roughly 45% of total consolidated revenue and benefits from rising home-ownership rates and heightened consumer spending on home-maintenance services; (3) Chemed’s adjusted EBITDA margin hovers around 16%-above the industry median of ~13%-reflecting operational efficiencies and franchise-model scalability. However, the company remains exposed to Medicare reimbursement policy changes and labor-cost pressures in both segments.
For a deeper dive into CHE’s valuation metrics, the ValueRay platform offers a concise, data-rich overview.
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income: 278.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA 4.53 > 1.0 |
| NWC/Revenue: 4.08% < 20% (prev 9.49%; Δ -5.41% < -1%) |
| CFO/TA 0.26 > 3% & CFO 419.7m > Net Income 278.8m |
| Net Debt (11.7m) to EBITDA (438.1m): 0.03 < 3 |
| Current Ratio: 1.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (14.5m) vs 12m ago -3.63% < -2% |
| Gross Margin: 32.24% > 18% (prev 0.36%; Δ 3188 % > 0.5%) |
| Asset Turnover: 149.2% > 50% (prev 134.3%; Δ 14.82% > 0%) |
| Interest Coverage Ratio: 114.2 > 6 (EBITDA TTM 438.1m / Interest Expense TTM 3.27m) |
Altman Z'' 10.00
| A: 0.06 (Total Current Assets 395.2m - Total Current Liabilities 292.0m) / Total Assets 1.62b |
| B: 1.78 (Retained Earnings 2.89b / Total Assets 1.62b) |
| C: 0.22 (EBIT TTM 373.7m / Avg Total Assets 1.70b) |
| D: 5.35 (Book Value of Equity 2.93b / Total Liabilities 546.9m) |
| Altman-Z'' Score: 13.31 = AAA |
Beneish M -2.93
| DSRI: 1.03 (Receivables 215.6m/196.5m, Revenue 2.53b/2.38b) |
| GMI: 1.11 (GM 32.24% / 35.66%) |
| AQI: 1.03 (AQ_t 0.55 / AQ_t-1 0.53) |
| SGI: 1.06 (Revenue 2.53b / 2.38b) |
| TATA: -0.09 (NI 278.8m - CFO 419.7m) / TA 1.62b) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of CHE shares?
Over the past week, the price has changed by +4.82%, over one month by +1.51%, over three months by +4.13% and over the past year by -18.79%.
Is CHE a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CHE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 555.5 | 24.1% |
| Analysts Target Price | 555.5 | 24.1% |
| ValueRay Target Price | 432.7 | -3.4% |
CHE Fundamental Data Overview February 02, 2026
P/E Forward = 16.9779
P/S = 2.4595
P/B = 5.6347
P/EG = 1.6989
Revenue TTM = 2.53b USD
EBIT TTM = 373.7m USD
EBITDA TTM = 438.1m USD
Long Term Debt = 141.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 42.0m USD (from shortTermDebt, last quarter)
Debt = 141.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.7m USD (from netDebt column, last quarter)
Enterprise Value = 6.24b USD (6.22b + Debt 141.5m - CCE 129.8m)
Interest Coverage Ratio = 114.2 (Ebit TTM 373.7m / Interest Expense TTM 3.27m)
EV/FCF = 17.30x (Enterprise Value 6.24b / FCF TTM 360.4m)
FCF Yield = 5.78% (FCF TTM 360.4m / Enterprise Value 6.24b)
FCF Margin = 14.24% (FCF TTM 360.4m / Revenue TTM 2.53b)
Net Margin = 11.02% (Net Income TTM 278.8m / Revenue TTM 2.53b)
Gross Margin = 32.24% ((Revenue TTM 2.53b - Cost of Revenue TTM 1.71b) / Revenue TTM)
Gross Margin QoQ = 28.91% (prev 29.85%)
Tobins Q-Ratio = 3.84 (Enterprise Value 6.24b / Total Assets 1.62b)
Interest Expense / Debt = 1.41% (Interest Expense 2.00m / Debt 141.5m)
Taxrate = 23.11% (19.3m / 83.5m)
NOPAT = 287.4m (EBIT 373.7m * (1 - 23.11%))
Current Ratio = 1.35 (Total Current Assets 395.2m / Total Current Liabilities 292.0m)
Debt / Equity = 0.13 (Debt 141.5m / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = 0.03 (Net Debt 11.7m / EBITDA 438.1m)
Debt / FCF = 0.03 (Net Debt 11.7m / FCF TTM 360.4m)
Total Stockholder Equity = 1.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.43% (Net Income 278.8m / Total Assets 1.62b)
RoE = 24.37% (Net Income TTM 278.8m / Total Stockholder Equity 1.14b)
RoCE = 29.07% (EBIT 373.7m / Capital Employed (Equity 1.14b + L.T.Debt 141.5m))
RoIC = 25.12% (NOPAT 287.4m / Invested Capital 1.14b)
WACC = 6.69% (E(6.22b)/V(6.37b) * Re(6.82%) + D(141.5m)/V(6.37b) * Rd(1.41%) * (1-Tc(0.23)))
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.44%
[DCF Debug] Terminal Value 84.21% ; FCFF base≈341.3m ; Y1≈376.3m ; Y5≈484.4m
Fair Price DCF = 799.2 (EV 11.29b - Net Debt 11.7m = Equity 11.28b / Shares 14.1m; r=6.69% [WACC]; 5y FCF grow 11.79% → 2.90% )
EPS Correlation: -35.52 | EPS CAGR: -46.10% | SUE: -4.0 | # QB: 0
Revenue Correlation: 94.74 | Revenue CAGR: 3.92% | SUE: -0.14 | # QB: 0
EPS next Quarter (2026-03-31): EPS=5.99 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=25.41 | Chg30d=-0.067 | Revisions Net=-1 | Growth EPS=+14.7% | Growth Revenue=+6.0%